High Court Won't Hear Orexigen Securities Fraud Suit
Law360 (May 20, 2019, 2:43 PM EDT) -- The U.S. Supreme Court declined on Monday to hear a challenge to a Ninth Circuit ruling that biotechnology company Orexigen had a duty to warn investors when new information about a drug conflicted with prior findings that were accurate when disclosed.
In an opinion that partially revived a stock-drop suit alleging misrepresentations about an obesity drug, the appellate panel had found in August that now-bankrupt Orexigen Therapeutics Inc. should have informed investors when it discovered that its drug did not actually offer the cardiovascular benefits suggested in earlier testing of the drug.
Executives for Orexigen petitioned the high court in January...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!